2026
NoPSC researchers awarded 9 million NOK to find new drug targets and biomarkers for primary sclerosing cholangitis.
Dr. Marit Mæhle Grimsrud’s doctoral work is focused on the strong need for better tools that can detect cancer earlier and guide more personalized treatment in patients with PSC. Grimsrud successfully defended her PhD on December 8h 2025.
NoPSC collaborate with scientists around the world, including our neighboring Swedish PSC-researchers. The one-day event in Stockholm February 5th, with more than 25 PSC-researchers, strengthened this collaboration.
Dr. Simen Hyll Hansen successfully defended his thesis “Diagnostic and Prognostic Potential of the Gut Microbiome in Inflammatory Bowel Disease”, on December 15th 2025.
European Association for study of the Liver arranges an annual congress, this year in Barcelona, May 27th to 30th. The EASL Congress is Europe’s largest event dedicated to liver health, with more than 8500 participants, 2000 abstracts and 190 presentations.
Experiments involving gnotobiotic mice is resource-intensive and always involves a certain risk of contamination. With the new facility this risk is significantly reduced.
NoPSC has several mechanisms in place to ensure the continuous high quality of our research, one of those is the Guest Professor program.
IPSCSG arranges biennial collaborative meetings for researchers with a unique focus on Primary Sclerosing Cholangitis (PSC) and all its aspects. This year the event was in Boston, USA, August 29th to 30th.
Dr. Tine Simensen Oldereid’s work explores how host-microbiota interactions and exposures to non-viable microbial components during early life influence immune development and inflammation. Oldereid successfully defended her PhD thesis on March 6th 2026.
The Norwegian Gastroenterological Society (Norsk Gastroenterologisk Forening, NGF) had its annual meeting in Lillehammer 29th to 31st of January 2026. NoPSC participated with several presentations of which three were awarded prizes.